Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)
Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –
Spero Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Spero Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $19.58M. For fiscal 2025 it was -$12.62M. The highest annual figure on record is -$7.73M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.62M | – |
| FY2024 | Dec 31, 2024 | -$23.44M | – |
| FY2023 | Dec 31, 2023 | -$33.00M | – |
| FY2022 | Dec 31, 2022 | -$7.73M | – |
| FY2021 | Dec 31, 2021 | -$64.35M | – |
| FY2020 | Dec 31, 2020 | -$85.87M | – |
| FY2019 | Dec 31, 2019 | -$50.02M | – |
| FY2018 | Dec 31, 2018 | -$39.63M | – |
| FY2017 | Dec 31, 2017 | -$39.11M | – |
| FY2016 | Dec 31, 2016 | -$28.96M | – |
| FY2015 | Dec 31, 2015 | -$9.61M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.36M | – |
| Q1 FY2026 | Mar 31, 2026 | $15.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.35M | – |
| Q3 FY2025 | Sep 30, 2025 | $17.42M | +36.5% |
| Q2 FY2025 | Jun 30, 2025 | -$17.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.00M | -167.4% |
| Q4 FY2024 | Dec 31, 2024 | -$23.40M | – |
| Q3 FY2024 | Sep 30, 2024 | $12.76M | -19.8% |
| Q2 FY2024 | Jun 30, 2024 | -$18.74M | – |
| Q1 FY2024 | Mar 31, 2024 | $5.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.49M | -139.3% |
| Q3 FY2023 | Sep 30, 2023 | $15.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.85M | – |
| Q4 FY2022 | Dec 31, 2022 | $44.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$957.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.03M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.57M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.33M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.37M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.66M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.07M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.92M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.51M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.51M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.64M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.96M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.74M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.52M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.88M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.98M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.20M | – |
See a number that looks wrong?